Extended Data Table 2 Summary of safety

From: Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial

  1. aThere were no grade 5 events.
  2. n (%), number of patients (percentage based on N); N, Number of patients.
  3. AEs, adverse events; ECIs, events of clinical interest; TEAEs, treatment-emergent adverse events.
Back to article page